메뉴 건너뛰기




Volumn 75, Issue 6, 2016, Pages 1166-1169

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

(20)  Unizony, Sebastian a   Villarreal, Miguel b   Miloslavsky, Eli M a   Lu, Na a   Merkel, Peter A c   Spiera, Robert d   Seo, Philip e   Langford, Carol A f   Hoffman, Gary S f   Kallenberg, C G M g   St Clair, E William h   Ikle, David b   Tchao, Nadia K i   Ding, Linna j   Brunetta, Paul k   Choi, Hyon K a   Monach, Paul A l   Fervenza, Fernando m   Stone, John H a   Specks, Ulrich m  


Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE 3 ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MYELOBLASTIN; PEROXIDASE;

EID: 84954288948     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208073     Document Type: Article
Times cited : (219)

References (20)
  • 1
    • 77954632414 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    • Jones R B, Tervaert J W, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20. .
    • (2010) N Engl J Med , vol.363 , pp. 211-220
    • Jones, R.B.1    Tervaert, J.W.2    Hauser, T.3
  • 2
    • 77954651554 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide for ANCA-associated vasculitis
    • Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
    • (2010) N Engl J Med , vol.363 , pp. 221-232
    • Stone, J.H.1    Merkel, P.A.2    Spiera, R.3
  • 3
    • 84908576790 scopus 로고    scopus 로고
    • Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis
    • Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80.
    • (2014) N Engl J Med , vol.371 , pp. 1771-1780
    • Guillevin, L.1    Pagnoux, C.2    Karras, A.3
  • 4
    • 0038122889 scopus 로고    scopus 로고
    • A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
    • Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
    • (2003) N Engl J Med , vol.349 , pp. 36-44
    • Jayne, D.1    Rasmussen, N.2    Andrassy, K.3
  • 5
    • 84880882979 scopus 로고    scopus 로고
    • Efficacy of remission-induction regimens for ANCA-associated vasculitis
    • Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27.
    • (2013) N Engl J Med , vol.369 , pp. 417-427
    • Specks, U.1    Merkel, P.A.2    Seo, P.3
  • 6
    • 84926432207 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide for ANCAassociated vasculitis with renal involvement
    • Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCAassociated vasculitis with renal involvement. J Am Soc Nephrol 2015;26:976-85.
    • (2015) J Am Soc Nephrol , vol.26 , pp. 976-985
    • Geetha, D.1    Specks, U.2    Stone, J.H.3
  • 7
    • 84935002700 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
    • Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis 2015;74:1178-82.
    • (2015) Ann Rheum Dis , vol.74 , pp. 1178-1182
    • Jones, R.B.1    Furuta, S.2    Tervaert, J.W.3
  • 8
    • 82755165229 scopus 로고    scopus 로고
    • Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) trial
    • Specks U, Seyfert-Margolis V, Merkel PA, et al. Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) trial. Open Arthritis J 2011;4:1-18.
    • (2011) Open Arthritis J , vol.4 , pp. 1-18
    • Specks, U.1    Seyfert-Margolis, V.2    Merkel, P.A.3
  • 9
    • 0028158243 scopus 로고
    • Nomenclature of systemic vasculitides. Proposal of an international consensus conference
    • Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
    • (1994) Arthritis Rheum , vol.37 , pp. 187-192
    • Jennette, J.C.1    Falk, R.J.2    Andrassy, K.3
  • 10
    • 0035053927 scopus 로고    scopus 로고
    • A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score
    • International Network for the Study of the Systemic Vasculitides (INSSYS)
    • Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
    • (2001) Arthritis Rheum , vol.44 , pp. 912-920
    • Stone, J.H.1    Hoffman, G.S.2    Merkel, P.A.3
  • 11
    • 0031042957 scopus 로고    scopus 로고
    • Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides
    • Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
    • (1997) Arthritis Rheum , vol.40 , pp. 371-380
    • Exley, A.R.1    Bacon, P.A.2    Luqmani, R.A.3
  • 12
    • 22244469119 scopus 로고    scopus 로고
    • Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    • Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78.
    • (2005) Arthritis Rheum , vol.52 , pp. 2168-2178
    • Seo, P.1    Min, Y.I.2    Holbrook, J.T.3
  • 13
    • 84926618081 scopus 로고    scopus 로고
    • Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function
    • McGregor JG, Negrete-Lopez R, Poulton CJ, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant 2015;30(Suppl 1):i171-81.
    • (2015) Nephrol Dial Transplant , vol.30 , pp. i171-i181
    • McGregor, J.G.1    Negrete-Lopez, R.2    Poulton, C.J.3
  • 14
    • 77953707436 scopus 로고    scopus 로고
    • Early mortality in systemic vasculitis: Relative contribution of adverse events and active vasculitis
    • Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1036-1043
    • Little, M.A.1    Nightingale, P.2    Verburgh, C.A.3
  • 15
    • 84856383829 scopus 로고    scopus 로고
    • Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
    • Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
    • (2012) Arthritis Rheum , vol.64 , pp. 542-548
    • Walsh, M.1    Flossmann, O.2    Berden, A.3
  • 16
    • 84869025741 scopus 로고    scopus 로고
    • Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis
    • Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
    • (2012) Arthritis Rheum , vol.64 , pp. 3452-3462
    • Lionaki, S.1    Blyth, E.R.2    Hogan, S.L.3
  • 17
    • 84903489572 scopus 로고    scopus 로고
    • Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: A study of 439 cases in a single Chinese center
    • Li ZY, Chang DY, Zhao MH, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 2014;66:1920-6.
    • (2014) Arthritis Rheumatol , vol.66 , pp. 1920-1926
    • Li, Z.Y.1    Chang, D.Y.2    Zhao, M.H.3
  • 18
    • 0033050247 scopus 로고    scopus 로고
    • Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients
    • Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
    • (1999) Arthritis Rheum , vol.42 , pp. 421-430
    • Guillevin, L.1    Durand-Gasselin, B.2    Cevallos, R.3
  • 19
    • 34250840592 scopus 로고    scopus 로고
    • ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
    • Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120:643.e9-14.
    • (2007) Am J Med , vol.120 , pp. 643.e9-643.e14
    • Finkielman, J.D.1    Lee, A.S.2    Hummel, A.M.3
  • 20
    • 0031658145 scopus 로고    scopus 로고
    • Antineutrophil cytoplasmic antibodies
    • Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-37.
    • (1998) Arthritis Rheum , vol.41 , pp. 1521-1537
    • Hoffman, G.S.1    Specks, U.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.